Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Phase I clinical trial data presented at the 2014 Breast Cancer Symposium shows that breast or ovarian tumors in people with BRCA mutations respond to treatment with veliparib. This phase I study was done with two different groups of patients: those with BRCA mutations, and those without BRCA mutations. In patients who did not have BRCA mutations, triple-negative breast cancer patients showed a small benefit. In patients with BRCA mutations, the overall response rate was 29% for breast cancer patients and 20% for ovarian cancer patients. Responses were higher with higher doses.
A phase II study in ovarian cancer showed a similar response rate to other PARP inhibitors for women with BRCA mutations.
AbbVie (a biopharmaceutical company), in partnership with the Gynecologic Oncology Group, recently opened a three-arm phase III study called GOG-3005 in newly-diagnosed women with advanced stage ovarian cancer (women with and without BRCA mutations are included) to test chemotherapy alone, versus chemotherapy with veliparib, versus chemotherapy combined with veliparib followed by veliparib maintenance therapy. Patients in GOG-3005 must be enrolled in the trial immediately after diagnosis and prior to the start of chemotherapy